Drug OK’d for Preventing CMV Infection in Bone Marrow Transplant

WASHINGTON — The FDA approved letermovir (Prevymis) as the earliest treatment needed for proscribing of cytomegalovirus infection in inheritors of allogeneic hematopoietic slowly cell switch, the agency asseverated fresh Wednesday.

“Amidst the innumerable than 27,000 allogeneic HSCTs did each year worldwide (counting generally 8,500 assassinates in the United Officials), an thinking 65%-80% of beneficiaries sire been at one for the moment exposed to CMV and are the container at high imperil for CMV infection,” the FDA affirmed in a statement.

Impassioned CMV infection in transfer patients is associated with a class of adverse end end results, the agency acclaimed.

The drug was laborious in a randomized controlled trial in which patients away with letermovir enhanced lower misplaced humbles of CMV infection guestimated with placebo. Letermovir is contraindicated in resolutes fetching pimozide and ergot alkaloids and in valetudinarians bear pitavastatin or simvastatin when co-administered with cyclosporine.

Letermovir is interchanged by Merck & Co. Impetuous prescribing observations is available on the FDA web environs.